Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy

Eagle Pharmaceuticals' PEMFEXY® received FDA approval for treating metastatic, non-squamous NSCLC without EGFR or ALK aberrations, marking its fifth indication. PEMFEXY, a ready-to-use liquid, eliminates reconstitution, offering advantages over ALIMTA®. Eagle amended its agreement to reduce future royalties, aiming to capture PEMFEXY's commercial potential.